指南与共识妇科肿瘤

ASCO 2026版活指南:PARP抑制剂在卵巢癌管理中的应用

PARP Inhibitors in the Management of Ovarian Cancer: ASCO Living Guideline, Version 2026.1.0.
指南 / 共识 · J Clin Oncol · 2026-10-27

该活指南基于79篇出版物(含18项HRD检测研究和31项关键试验)的系统综述,为上皮性卵巢癌中PARP抑制剂的使用提供推荐。一线试验显示无进展生存获益,但后线治疗和复发维持试验报告可能的总体生存劣势。推荐所有新诊断晚期患者进行遗传检测,BRCA阴性者行HRD肿瘤检测;PARP抑制剂维持治疗应优先用于首次临床缓解,且主要限于BRCA突变或HRD阳性患者。

要点

  • 所有新诊断晚期上皮性卵巢癌患者均应行遗传检测,BRCA阴性者补充HRD肿瘤检测。
  • PARP抑制剂维持治疗应优先用于一线化疗后的首次临床缓解。
  • 复发维持治疗主要限于未接受过PARP抑制剂的BRCA突变且铂类敏感患者。

核心结论

  • 一线PARP抑制剂维持治疗在BRCA突变或HRD阳性晚期上皮性卵巢癌中显示无进展生存获益。
  • 后线治疗和复发维持试验报告潜在的总体生存劣势,复发维持应主要限于未接受过PARP抑制剂的BRCA突变患者。

研究设计与样本

  • ASCO专家小组基于随机对照试验和队列研究的系统综述制定活指南。
  • 更新证据库包含79篇出版物,包括18项评估13种HRD检测方法的研究和31项评估PARP抑制剂疗效与安全性的关键试验。

主要发现

  • 一线试验显示无进展生存获益。
  • 后线治疗和复发维持试验报告潜在的总体生存劣势。

关键数值与推荐

  • 所有新诊断晚期上皮性卵巢癌患者应接受遗传检测,BRCA阴性者应使用FDA批准或前瞻性验证的伴随诊断方法行HRD肿瘤检测。
  • 晚期上皮性卵巢癌中,PARP抑制剂维持治疗应优先用于首次临床缓解。
  • 一线PARP抑制剂单药维持治疗应提供给铂类化疗后缓解的胚系或体细胞BRCA1/2突变或HRD阳性患者。
  • 奥拉帕利联合贝伐珠单抗维持治疗可提供给一线铂类化疗联合贝伐珠单抗缓解的BRCA1/2突变或HRD阳性患者。
  • 非BRCA突变HRD阴性肿瘤或早期上皮性卵巢癌患者不推荐PARP抑制剂维持治疗。

临床怎么用

  • 临床医生应监测严重不良事件,包括骨髓增生异常综合征、急性髓系白血病和肺部并发症。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This living guideline provides recommendations on the use of poly(ADP-ribose) polymerase inhibitors (PARPis) in the management of epithelial ovarian cancer (EOC). METHODS: An Expert Panel developed recommendations based on a systematic review of randomized controlled trials, and cohort studies evaluating homologous recombination deficiency (HRD) testing and PARPi efficacy and safety. RESULTS: The updated evidence base comprises 79 publications, including 18 studies evaluating 13 homologous recombination deficiency (HRD) assays and 31 pivotal trials assessing PARPi efficacy and safety. Frontline trials demonstrated progression-free survival benefits. However, later-line treatment and recurrent maintenance trials reported potential overall survival disadvantages. RECOMMENDATIONS: All patients with newly diagnosed advanced EOC should undergo genetic testing, and HRD tumor testing if BRCA-negative, using FDA-approved or prospectively validated companion diagnostic assays. In advanced EOC, PARPi maintenance should be prioritized for the first clinical remission. Frontline PARPi monotherapy maintenance should be offered after platinum-based chemotherapy response to patients with germline or somatic BRCA1/2 mutations or HRD-positive disease. Olaparib plus bevacizumab maintenance may be offered to patients responding to first-line platinum-based chemotherapy plus bevacizumab who have BRCA1/2 mutations or HRD-positive disease. PARPi maintenance therapy is not recommended for patients with non-BRCAmut HRD-negative tumors or early-stage EOC. In the recurrent setting, PARPi maintenance should be restricted primarily to PARPi-naïve patients with BRCA1/2 mutations responding to second-line or greater platinum-based chemotherapy. Monotherapy PARPi should not be offered for the treatment of recurrent EOC outside clinical trials. Furthermore, PARPi are not recommended for use in combination with chemotherapy, other targeted agents, or immune-oncology agents outside a clinical trial. Clinicians should monitor for serious adverse events, including myelodysplastic syndrome, acute myeloid leukemia, and pulmonary complications.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Tew WP, Lacchetti C, Adams TS, et al. PARP Inhibitors in the Management of Ovarian Cancer: ASCO Living Guideline, Version 2026.1.0. J Clin Oncol. 2026. PMID: 42945508. doi:10.1200/JCO-26-02412

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。